**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 65981

**Manuscript Type:** REVIEW

**Role of cardiac magnetic resonance imaging in troponinemia syndromes**

NguyenNguyenN *et al*. Cardiac MRI in troponinemia syndromes

Nhung Nguyen Nguyen, Joseph George Assad, Giuseppe Femia, Andreas Schuster, James Otton, Tuan Le Nguyen

**Nhung Nguyen Nguyen, Joseph George Assad, James Otton,** department of Cardiology, Liverpool Hospital, Liverpool 2170, NSW, Australia

**Giuseppe Femia,** Department of Cardiology, Campbelltown Hospital, Campbelltown 2560, NSW, Australia

**Andreas Schuster,** Department of Cardiology and Pneumology, University Medical Center, Göttingen 37075, Germany

**Tuan Le Nguyen,** Department of Cardiology, Liverpool Hospital, Liverpool 2170, NSW, Australia

**Author contributions:** Nguyen Nguyen N was responsible for concept and design of manuscript, and wrote the first original draft (except section on Takotsubo cardiomyopathy); Assad JG provided the first original draft for the Takotsubo cardiomyopathy section and Table 1; Assad JG, Femia G, Otton J and Schuster A collected or provided the cardiac magnetic resonance images; Nguyen Nguyen N, Femia G, Schuster A, Otton J and Nguyen TL were the main contributors towards critical revisions related to important intellectual content of the manuscript; and all authors provided the approval of the final version of the article to be published.

**Corresponding author: Tuan Le Nguyen, FRACP, MBBS, PhD, Staff Physician,** Department of Cardiology, Liverpool Hospital, Locked Bag 7103, Liverpool 2170, NSW, Australia. nguyenletuan@hotmail.com

**Received:** March 18, 2021

**Revised:** November 13, 2021

**Accepted:** April 3, 2022

**Published online:** April 26, 2022

**Abstract**

Cardiac magnetic resonance imaging (MRI) is an evolving technology, proving to be a highly accurate tool for quantitative assessment. Most recently, it has been increasingly used in the diagnostic and prognostic evaluation of conditions involving an elevation in troponin or troponinemia. Although an elevation in troponin is a nonspecific marker of myocardial tissue damage, it is a frequently ordered investigation leaving many patients without a specific diagnosis. Fortunately, the advent of newer cardiac MRI protocols can provide additional information. In this review, we discuss several conditions associated with an elevation in troponin such as myocardial infarction, myocarditis, Takotsubo cardiomyopathy, coronavirus disease 2019 related cardiac dysfunction and athlete’s heart syndrome.

**Key words:** Cardiac magnetic resonance imaging; Troponin; Myocardial infarction; Myocarditis; Takotsubo cardiomyopathy; COVID-19; Athlete’s heart

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Nguyen Nguyen N, Assad JG, Femia G, Schuster A, Otton J, Nguyen TL. Role of cardiac magnetic resonance imaging in troponinemia syndromes. *World J Cardiol* 2022; 14(4): 190-205

**URL:** https://www.wjgnet.com/1949-8462/full/v14/i4/190.htm

**DOI:** https://dx.doi.org/10.4330/wjc.v14.i4.190

**Core tip:** Cardiac magnetic resonance has excellent spatial resolution to assess ventricular volumes and function. It is also continuing to evolve to provide key diagnostic and prognostic information particularly through the use of gadolinium contrast agent for the conditions presented in this review.

**INTRODUCTION**

Troponinemia describes an elevation in serum troponin levels that can result from a myriad of conditions such as acute myocardial infarction (AMI), takotsubo cardiomyopathy (TTS), myocarditis and athlete’s heart syndrome (AHS). More recently, severe acute respiratory syndrome coronavirus 2 has been linked to cardiac disease and elevated troponin levels. Given that troponinemia is nonspecific, establishing a definitive diagnosis can be difficult. Fortunately, cardiac magnetic resonance imaging (CMRI) has the ability to characterise myocardial tissue and identify unique pathological features of cardiac disease. As a diagnostic tool for these conditions, CMRI imaging may be promising.

This narrative review gives an overview of the diagnostic features and potential role of CMRI in conditions associated with troponinemia such as myocardial infarction (MI), TTS, myocarditis, coronavirus disease 2019 (COVID-19) related cardiovascular disease and AHS (Table 1).

**MI**

AMI is one of the most common causes of elevated troponin levels. It is defined by the presence of acute myocardial injury in conjunction with dynamic changes in troponin levels, and evidence of myocardial ischaemia[1]. Electrocardiography (ECG), transthoracic echocardiography (TTE) and invasive coronary angiography are the standard of care in the evaluation of MI. Adjunctive use of CMRI can be useful to confirm the diagnosis, assess chronicity, guide management and aid prognosis. It can be utilised to distinguish the changes seen between an acute and an established, or also called chronic, MI. CMRI is also highly accurate at assessing ventricular volumes and function with superior spatial resolution, contrast-to-noise ratio and tissue characterisation compared to TTE.

On CMRI, AMI can demonstrate ventricular regional wall motion abnormalities (RWMAs) corresponding with the affected vascular territory on cine images. Intramyocardial haemorrhage may occur, and is represented by a hypointense zone in the infarcted area on T2-imaging or mapping[2]. Following ischaemic insult from coronary artery obstruction, myocardial cellular injury begins in the subendocardial region, and continues to extend towards the subepicardium if there is ongoing oxygen deprivation. This process is known as the “wavefront phenomenon of myocardial death”, named by Reimer *et al*[3]. Late gadolinium enhancement images characteristically demonstrate a hypodense core surrounded by an area of hyperenhancement (Figure 1), and is found in a subendocardial or transmural distribution depending on the extent of the MI[4-6]. In chronic MI (CMI), cine images will typically show wall thinning, RWMA, and a lack of oedema on T2-weighted images[7]. In a study by Rehwald *et al*[8], the authors used rabbit models to demonstrate that gadolinium contrast agent uptake was greater in infarcted myocardial tissue. In another study, Kim *et al*[9] demonstrated that the extent of transmural hyperenhancement reflected the degree of irreversible injury. Native T1-sequences have also been explored by Kali *et al*[10], who demonstrated CMRI may be useful in diagnosing CMI, and determining likely irreversible injury. It is particularly useful in some situations, such as in renal failure patients, where gadolinium contrast is contraindicated.

Besides determining left ventricular ejection fraction (LVEF) on cine imaging, a detailed assessment of LV deformation measurements can also take place using CMRI[11]. Left ventricular global radial strain, circumferential strain and global longitudinal strain (GLS) have all shown association with increased major adverse cardiac events (MACEs)[12], and GLS has been demonstrated to be an independent predictor of post-MI clinical outcome. Impairment of left atrial strain on CMRI post-MI has also been demonstrated to be an independent predictor for increase in MACEs, as well as improving prognostic value when combined with LVEF[13,14].

It has been demonstrated that in patients with coronary artery disease, those treated with revascularisation have a significantly lower annual mortality rate compared to those treated with medical therapy[15,16]. In these patients, CMRI can be used to assess the viability of a coronary artery territory. The most important parameters are LV end-diastolic wall thickness, quantitative LV systolic or diastolic performance during low-dose dobutamine stress testing, and late gadolinium enhancement (LGE)[17]. For example, in a LV segment with ≤ 50% transmural LGE, a normal dobutamine response is correlated with greater functional recovery after revascularisation[18,19]. In contrast, the presence of ≥ 50% transmural LGE indicates nonviable infarcted tissue[20,21]. This technique is comparable to fluorodeoxyglucose positron emission tomography, which is considered the gold standard in the assessment of myocardial viability[22]. Unfortunately, the role of CMRI can be limited in many healthcare settings, considering factors including machine access, availability of imaging experts, cost and time.

The use of CMRI in assessing prognosis following MI has shown promising results. Assessment for microvascular obstruction (MVO) through the use of first pass perfusion studies during and following gadolinium contrast administration is one of the prognostic features that has been studied. It is implicated in adverse ventricular remodelling, larger infarct size (IS) and poorer clinical outcome[23-25]. van Kranenburg *et al*[26] have also demonstrated that MVO is an independent predictor for major adverse clinical outcomes at 2 years. Infarct size on CMRI has also been shown to be strongly associated with heart failure hospitalisation and all-cause mortality[27]. More recently, postcontrast T1 mapping has been shown to accurately quantify IS in a small study[28]. CMRI has also demonstrated some correlation between IS and peak troponin I[29], however this has not been a consistent or reliable finding. Intramyocardial haemorrhage has been linked to adverse LV remodelling and increased MACEs, but heterogeneity in imaging techniques mean further study is required[23]. The presence of LGE in patients with symptoms suggestive of MI conferred worse MACEs compared to those without LGE[30]. The prognostic importance of LVEF has been demonstrated in a number of studies[31,32]. Study delay for at least 1 wk following AMI should be considered, to allow for myocardial functional recovery as found by Mather *et al*[33], and further imaging at up to 6 mo may be required to assess stabilised LVEF[34]. LVEF ≤ 35% and LGE were independently associated with MACEs, with better predictive value than TTE[35]. The extent of LV scarring has also been clearly associated with risk of spontaneous ventricular arrhythmias[36-38]. Assessment of the peri-infarct, or “grey-zone”, surrounding the infarcted core may also play a role in risk stratifying post-MI patients, with increased size posing potential heightened ventricular arrhythmic risk[39]. Yan *et al*[40] used a semiautomatic software detection system to quantify percentage of abnormal myocardial delayed enhancement of tissue surrounding the infarct core, and noted that it was an independent predictor of post-MI all-cause and cardiovascular mortality.

Incorporation of artificial intelligence-based analyses will likely have a role to play in the future in cardiac outcome and prognosis prediction. It has already been demonstrated that fully automated volumetric and myocardial segmentation assessment are equally effective as manual efforts in predicting MACEs[41].

As it stands, without the availability of randomised controlled data or larger studies, the actions to be taken if high risk CMRI features are seen are not completely clear[42,43].

**TTS**

TTS, which is also known as Takotsubo cardiomyopathy, transient apical ballooning syndrome, broken heart syndrome and stress-induced cardiomyopathy, is a condition of transient LV dysfunction that is typically triggered by physical or emotional stress[44]. TTS mimics MI with often indistinguishable clinical presentation, ECG changes and cardiac enzyme elevation, but without angiographic evidence of acute obstructive coronary artery disease or plaque rupture[44,45]. Given the transient nature of TTS, traditionally it was thought of as a benign condition however more recent data suggests this is misguided, with complications comparable to those seen in patients with the acute coronary syndrome[46,47]. CMRI is increasingly used to diagnose and evaluate complications of TTS in both the acute and subacute setting, particularly in those with atypical features, or bystander coronary artery disease[48].

In the acute setting, CMRI can define TTS by excluding other aetiologies such as MI and myocarditis and identifying RWMAs that extend beyond a single coronary artery distribution[49] (Figure 2). One of the hallmarks is reversible myocardial inflammation corresponding to RWMA[31,44]. CMRI can assess myocardial inflammation and oedema with T2-weighted images[44,50-52].

In the subacute phase, its strength in identifying subtle RWMA makes it the ideal modality to accurately assess for resolution of regional dysfunction, with full recovery being a criteria confirmation of diagnosis[44].

Late gadolinium-enhanced imaging is a valuable adjunct in confirming a diagnosis of TTS when there is coexisting coronary artery disease or suspicion for myocarditis. It is widely believed that in TTS, there is an absence of LGE on CMRI[31], however, there are studies challenging this notion, having demonstrated LGE in patients with TTS in the acute phase[52-54]. It should be noted that LGE in this setting is transient, resolving on serial imaging to confirm the diagnosis of TTS, and has been associated with increased incidence cardiogenic shock and a longer timeframe for resolution of wall motion abnormalities[55,56].In contrast, patients with myocardial infarction will have focal subendocardial or transmural LGE evident, while those with myocarditis typically will have a mid-wall distribution of LGE[57].

In addition to confirming the diagnosis of TTS, CMRI is useful in identifying complications such as mitral regurgitation and LV outflow tract obstruction seen on blood flow imaging, pericardial effusion seen on black blood T1-weighted sequences, and ventricular (including apical) thrombi not visualised on TTE, during early gadolinium (EGE) sequences. Thrombi will appear as a low signal intensity without gadolinium uptake, in comparison to the high intensity signal from the blood pool[50,52].

It has been hypothesised that the elevated catecholamines observed in TTS have a role in the microvascular dysfunction noted in patients with TTS, correlating with improvement in myocardial function[58]. While not established in TTS, there is emerging evidence in the utility of quantitative perfusion CMRI to more objectively assess the role that microvascular dysfunction plays in this syndrome, and is subject to further research[59].

**Acute Myocarditis**

Acute myocarditis is an inflammatory cardiomyopathy secondary to infectious and noninfectious conditions, sometimes associated with symptoms of heart failure developing over ≤ 3 mo. The clinical presentation can be nonspecific and may include chest pain, heart failure, cardiogenic shock, arrhythmias and/or sudden cardiac death. Early investigations may demonstrate elevated troponin levels, elevated acute phase reactants such as C-reactive protein, erythrocyte sedimentation rate and eosinophil count. An ECG may be normal, show nonspecific abnormalities or be similar to the pattern of acute pericarditis and AMI. Most importantly, it is important to exclude alternative causes such as MI. Due to the variable clinical presentation, the gold standard for diagnosis remains an endomyocardial biopsy (EMB), which is an invasive procedure that carries risk of life-threatening complications. CMRI may provide a noninvasive alternative for the assessment of myocarditis[60].

CMRI has become an important tool in the assessment of myocardial inflammation in patients with suspected myocarditis. Assessment of gross abnormalities includes changes in ventricular size and geometry, regional and global wall motion abnormalities and identification of pericardial effusion. In addition, there are techniques to assess microscopic markers of myocardial inflammation such as T1-weighted sequences for detection of myocardial hyperaemia, LGE for myocardial necrosis, fibrosis or scars and T2-weighted imaging to identify oedema[61-63]. Following early CMRI data, consensus diagnostic criteria were released and incorporated into the Lake Louise criteria[60] (LLC) (Table 2). The use of newer mapping techniques such as for native T1 and T2, and quantification of extracellular volume (ECV), in comparison to the LLC, appear superior in the diagnosis of acute myocarditis, with positive predictive value of 90% *versus* 71%[64].

LGE has been shown to be highly accurate in the diagnosis of myocarditis with a high correlation with EMB[65]. Acute myocarditis is associated with subepicardial or mid-wall late gadolinium enhancement most commonly in the lateral, inferolateral or inferior wall[66-68] (Figure 3). In particular, small studies have suggested specific patterns for certain viruses: parvovirus B19 is associated with the lateral wall while human herpes virus 6 is linked to the septal wall[69]. The presence of LGE on follow-up studies denotes areas of irreversible myocardial injury[62,65].

CMRI diagnostic accuracy in the workup for chronic myocarditis (> 14 d) is not as well established compared to acute myocarditis, with T2-mapping providing the only discernible additional diagnostic benefit together with the LLC[66,70].

Although CMRI has demonstrated prognostic guidance in acute myocarditis, cardiac enzyme markers do not reflect the degree of myocardial injury or permanent scarring as demonstrated on CMRI LGE[70]. There are insufficient data available to relate CMRI features to independent risk of ventricular arrhythmias, although this is clearly raised in the context of impaired LV function[67,71]. In a meta-analysis, the presence of LGE, particularly anteroseptal location, has been found to be an independent risk factors for adverse cardiac outcomes, including all-cause mortality, cardiac mortality including sudden cardiac death, and MACEs[72].

**Covid-19 related cardiac dysfunction**

COVID-19 infection has variable presentations, most commonly involving respiratory symptoms. However, since the declaration of the pandemic in March 2020, there have been increasing reports of cardiovascular disease. The incidence has been reported to be ≥ 40%, depending on the definition or population sampled[73-76]. Postmortem studies of confirmed COVID-19 cases have demonstrated the presence of the virus in the myocardium, but not necessarily with consistent expression of cardiac sequelae[77]. There are numerous mechanisms involved in myocardial injury, which include direct viral invasion and host innate immunity response, hypoxia, micro- and macrovascular thrombosis, inflammatory injury and stress-induced cardiomyopathy[78].

Considering the multifaceted components of COVID-19-induced myocardial injury, it should not be expected that the imaging findings of this infection would duplicate that of a viral myocarditis syndrome alone. Cardiac involvement in COVID-19 infection may not be present with clinically severe cardiac symptoms[75,79], and even though echocardiography is a sensitive tool to identify gross cardiac dysfunction, LVEF may be normal[77]. There have been reports of primary cardiac involvement in COVID-19 [80], where CMRI can be useful in identifying acute viral myocarditis features, as well as evidence of thrombosis such as LV apical thrombus.

Studies using CMRI have demonstrated the severity of cardiovascular involvement following acute infection. In a report by Huang *et al*[81], the authors noted that 57% of patients had myocardial oedema or LGE on CMRI performed > 1 mo after development of infection (Figure 4). This suggests an ongoing pathological process affecting the myocardium. Historically, the LGE distribution in acute viral myocarditis involved the lateral and inferior walls. However with COVID-19, LGE patterns have been reported as subepicardial, mid-wall or subendocardial mimicking AMI[75]. Of note, there are no studies available where participants have baseline cardiac MRI data prior to COVID-19 infection. In addition, T2-signal hyperintensity tended to favour the interventricular septum, anterior and anterolateral walls, as well as basal inferior and mid-chamber. T1-mapping and ECV also demonstrated increased values, suggestive of myocardial fibrosis[75,81].

A developing use for CMRI is in the diagnosis suspected COVID-19-vaccine-associated myocarditis. These events tend to occur more frequently in young male patients after the second dose of mRNA vaccine[82,83]. Patients typically present with chest pain, troponin elevations, and abnormal CMRI findings[84]. CMRI abnormalities include myocardial oedema, hyperaemia and LGE, which are expected findings in acute myocarditis[85-89]. To date, there are no specific features for COVID-19-vaccine-associated myocarditis.

Evidence for the outcome of COVID-19-induced myocardial injury continues to evolve. Studies have found that elevation in troponin T levels confer significantly increased risk of mortality[73,90,91]. However, whether this and other markers of myocardial injury are byproducts of disease severity, or directly contribute to morbidity and mortality, remains to be elucidated. Currently, there is no long-term data on COVID-19 effects on the cardiovascular system, but considering its global impact, the identification, monitoring and study of outcomes is critical, with CMRI likely to play an essential role[92,93].

**High-endurance athletes and AHS**

Competitive sports level training can lead to a condition known as AHS, defined by complex cardiac chamber remodelling, ventricular systolic impairment and abnormalities involving the electrical conduction system. Electrocardiogram changes can include first-degree atrioventricular block, incomplete right bundle branch block, early repolarisation and isolated increased QRS voltages that may meet criteria for LV hypertrophy (LVH)[94]. Transient troponin elevation occurs with moderate-to-high intensity exercise[95,96]. The role of CMRI is also continuing to evolve in helping distinguish AHS from conditions such as hypertrophic cardiomyopathy (HCM) and arrhythmogenic cardiomyopathy (ACM), which can have similar ECG and TTE features.

Although ventricular hypertrophy and dilatation can occur in both ventricles, impairment of systolic function following prolonged exercise tends to observed more frequently in the right ventricle (Figure 5A). In early forms of the disease, diastolic dysfunction is often observed, first defined by a reduction in mitral E:A ratio on echocardiographic Doppler imaging[97-100]. A hallmark of AHS is increased LV mass[101]. Unfortunately, this is not a discriminating feature and can overlap with other conditions such as HCM and ACM[102]. In particular, differentiating AHS from mild HCM, with LV wall thickness range 13–15 mm, is critical in preventing adverse outcomes for athletes. Despite early reports suggesting that different cardiac conditions can lead to particular patterns of LVH, this has not been demonstrated in subsequent studies[103,104].Cessation of training usually leads to LVH regression and improvement in clinical outcomes.

The advancement of CMRI technology may help shed light on the potential long-term effects of competitive level exercise and help differentiate different cardiac conditions. LV cavity size (LV end-diastolic and end-systolic diameter) in AHS is usually larger than HCM, particularly if the end-diastolic diameter exceeds 54 mm[100]. CMRI can also provide accurate morphology assessment for excessive trabeculation and noncompaction cardiomyopathy, if it cannot be clearly delineated on echocardiography[105]. The use of more advanced CMRI tissue characterisation techniques such as T1 mapping and ECV assessment is also helpful. Athletes have been demonstrated to have lower ECV, likely as a result of myocyte enlargement, compared to nonathletes. Conversely, in HCM, there is increased ECV[106,107].The role of LGE to distinguish AHS compared to HCM is not yet certain. Domenech-Ximenos *et al*[106] found that focal LGE was more prevalent in intensive endurance athletes compared to healthy subjects (37.6% *vs* 2.8%), with a typical pattern at the right ventricular (RV) insertion points. This may overlap with the LGE distribution in HCM[107].

Ventricular dilatation has been noted in athletes compared to healthy nonathletic individuals[108,109]. LV dilatation is less severe as compared to the RV dilatation. Stress echocardiography observation of improvement in LVEF by > 11%, and presence of mid-wall LGE may help to discriminate between AHS and pathological dilated cardiomyopathy[95,96,110,111] but this has not yet been investigated in large studies. In a meta-analysis performed by D’Ascenzi *et al*[102], in high-performance athletes, RV end-diastolic volume (EDV) and end-systolic volume (ESV) exhibited the greatest relative increase in ventricular remodelling, compared to baseline parameters. This may be in response to increased venous return and other hemodynamic changes. The increase in RV size in athletes has led to situations where the dimensions meet part of the ACM criteria[112]. CMRI can be useful to improve spatial resolution in cases with poor echocardiographic windows. It can quantify function, identify RWMAs, and determine the presence of myocardial fibrosis and fibrofatty infiltration, to evaluate ACM versus AHS. In one study, Zaidi *et al*[113] found that the presence of RV ejection fraction < 45%, the ratio of RV EDV to LV EDV > 1.1/1, RV RWMA and LGE found together in athletes was highly indicative of ACM.

Exercise CMRI may provide addition diagnostic information by comparing the difference between adaptive responses and ventricular pathology in AHS, as well as potential prognostic information. The development of in-scanner CMRI exercise protocols with excellent reproducibility has been important in facilitating studies on the difference in physiological and pathological responses of athletes[114,115]. During exercise, elite athletes with evidence of ventricular arrhythmias had an increase in RV EDV, decrease in RV ESV, and, as a result, had reduced RV ejection fraction compared to athletes with no evidence of ventricular arrhythmia and healthy controls[116]. Of note, stress TTE yielded similar sensitivity in identifying exercise induced RV dysfunction.

The use of CMRI has been explored in AHS adverse outcome prognostication. In the context of excellent spatial and temporal resolution of CMRI, there appears to be no difference in resting in cardiac volumes of elite athletes with and without evidence of ventricular arrhythmias[116]. LGE at the junction of the right ventricle and interventricular septum has previously been noted in athletes, but is not related to any clinical sequelae. A pattern of myocardial wall fibrosis in AHS has otherwise not consistently been demonstrated, or has been affected by confounding factors such as veteran athletes with coronary artery atherosclerotic plaques[112,117-119] (Figure 5B–5D). Zorzi *et al*[120] did note that in athletes who presented with a history of ventricular arrhythmias and subsequently found to have LV LGE, a striae subepicardial – midmyocardial lateral LV wall distribution pattern was more prevalent. There are no long-term data on outcome of incidental finding of myocardial LGE[114,121-123]. The definitive role of CMRI for prognostication in AHS remains to be defined outside of its roles in excluding other important diagnoses such as HCM and ARC.

**Comments and Limitations**

Traditionally, gross morphological cine scanning and determination of LGE location in the myocardial wall has formed key diagnostic features in the use of CMRI for many conditions. The advent of more advanced techniques such as T1 and T2 mapping has allowed a deeper understanding of the pathophysiological process involved.

The limitations for the use of CMRI include: (1) access to CMR facilities with trained staff to perform the scan and process the images; (2) standardised protocols; (3) duration of procedure; (4) high cost; and (5) lack of superiority to cheaper, faster and more accessible imaging modalities.

Moving forward, improving access to CMRI, increasing the number of skilled personnel and developing clear scanning guidelines are needed. Further research including large randomised trials are necessary to further define the role of CMRI in the assessment of MI, TTS, myocarditis, AHS and COVID-19-related cardiac conditions.

**Conclusion**

Troponinemia or an elevation in serum troponin levels can result from several different conditions making the diagnosis difficult. CMRI provides a powerful insight into the pathological mechanisms of disease, diagnostic features, as well as potential prognosis. With advancement in technology and research, this will only continue to improve.

**References**

1 **Thygesen K**, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). *Circulation* 2018; **138**: e618-e651 [PMID: 30571511 DOI: 10.1161/CIR.0000000000000617]

2 **Bulluck H**, Dharmakumar R, Arai AE, Berry C, Hausenloy DJ. Cardiovascular Magnetic Resonance in Acute ST-Segment-Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions. *Circulation* 2018; **137**: 1949-1964 [PMID: 29712696 DOI: 10.1161/CIRCULATIONAHA.117.030693]

3 **Reimer KA**, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. *Circulation* 1977; **56**: 786-794 [PMID: 912839 DOI: 10.1161/01.cir.56.5.786]

4 **Ichikawa Y**, Sakuma H, Suzawa N, Kitagawa K, Makino K, Hirano T, Takeda K. Late gadolinium-enhanced magnetic resonance imaging in acute and chronic myocardial infarction. Improved prediction of regional myocardial contraction in the chronic state by measuring thickness of nonenhanced myocardium. *J Am Coll Cardiol* 2005; **45**: 901-909 [PMID: 15766827 DOI: 10.1016/j.jacc.2004.11.058]

5 **Thiele H**, Kappl MJ, Conradi S, Niebauer J, Hambrecht R, Schuler G. Reproducibility of chronic and acute infarct size measurement by delayed enhancement-magnetic resonance imaging. *J Am Coll Cardiol* 2006; **47**: 1641-1645 [PMID: 16631003 DOI: 10.1016/j.jacc.2005.11.065]

6 **Mahrholdt H**, Wagner A, Holly TA, Elliott MD, Bonow RO, Kim RJ, Judd RM. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. *Circulation* 2002; **106**: 2322-2327 [PMID: 12403661 DOI: 10.1161/01.CIR.0000036368.63317.1C]

7 **Rajiah P**, Desai MY, Kwon D, Flamm SD. MR imaging of myocardial infarction. *Radiographics* 2013; **33**: 1383-1412 [PMID: 24025931 DOI: 10.1148/rg.335125722]

8 **Rehwald WG**, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. *Circulation* 2002; **105**: 224-229 [PMID: 11790705 DOI: 10.1161/hc0202.102016]

9 **Kim HW**, Farzaneh-Far A, Kim RJ. Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. *J Am Coll Cardiol* 2009; **55**: 1-16 [PMID: 20117357 DOI: 10.1016/j.jacc.2009.06.059]

10 **Kali A**, Choi EY, Sharif B, Kim YJ, Bi X, Spottiswoode B, Cokic I, Yang HJ, Tighiouart M, Conte AH, Li D, Berman DS, Choi BW, Chang HJ, Dharmakumar R. Native T1 Mapping by 3-T CMR Imaging for Characterization of Chronic Myocardial Infarctions. *JACC Cardiovasc Imaging* 2015; **8**: 1019-1030 [PMID: 26298071 DOI: 10.1016/j.jcmg.2015.04.018]

11 **Ersbøll M**, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P, Køber L. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. *J Am Coll Cardiol* 2013; **61**: 2365-2373 [PMID: 23563128 DOI: 10.1016/j.jacc.2013.02.061]

12 **Eitel I**, Stiermaier T, Lange T, Rommel KP, Koschalka A, Kowallick JT, Lotz J, Kutty S, Gutberlet M, Hasenfuß G, Thiele H, Schuster A. Cardiac Magnetic Resonance Myocardial Feature Tracking for Optimized Prediction of Cardiovascular Events Following Myocardial Infarction. *JACC Cardiovasc Imaging* 2018; **11**: 1433-1444 [PMID: 29454776 DOI: 10.1016/j.jcmg.2017.11.034]

13 **Schuster A**, Backhaus SJ, Stiermaier T, Navarra JL, Uhlig J, Rommel KP, Koschalka A, Kowallick JT, Lotz J, Gutberlet M, Bigalke B, Kutty S, Hasenfuss G, Thiele H, Eitel I. Left Atrial Function with MRI Enables Prediction of Cardiovascular Events after Myocardial Infarction: Insights from the AIDA STEMI and TATORT NSTEMI Trials. *Radiology* 2019; **293**: 292-302 [PMID: 31526253 DOI: 10.1148/radiol.2019190559]

14 **Nayyar D**, Nguyen T, Pathan F, Vo G, Richards D, Thomas L, Dimitri H, Otton J. Cardiac magnetic resonance derived left atrial strain after ST-elevation myocardial infarction: an independent prognostic indicator. *Cardiovasc Diagn Ther* 2021; **11**: 383-393 [PMID: 33968617 DOI: 10.21037/cdt-20-879]

15 **Allman KC**, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. *J Am Coll Cardiol* 2002; **39**: 1151-1158 [PMID: 11923039 DOI: 10.1016/s0735-1097(02)01726-6]

16 **Hachamovitch R**, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. *Circulation* 2003; **107**: 2900-2907 [PMID: 12771008 DOI: 10.1161/01.CIR.0000072790.23090.41]

17 **Charoenpanichkit C**, Hundley WG. The 20 year evolution of dobutamine stress cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2010; **12**: 59 [PMID: 20977757 DOI: 10.1186/1532-429X-12-59]

18 **Bove CM**, DiMaria JM, Voros S, Conaway MR, Kramer CM. Dobutamine response and myocardial infarct transmurality: functional improvement after coronary artery bypass grafting--initial experience. *Radiology* 2006; **240**: 835-841 [PMID: 16926330 DOI: 10.1148/radiol.2403051150]

19 **Motoyasu M**, Sakuma H, Ichikawa Y, Ishida N, Uemura S, Okinaka T, Isaka N, Takeda K, Nakano T. Prediction of regional functional recovery after acute myocardial infarction with low dose dobutamine stress cine MR imaging and contrast enhanced MR imaging. *J Cardiovasc Magn Reson* 2003; **5**: 563-574 [PMID: 14664134 DOI: 10.1081/jcmr-120025233]

20 **Hillenbrand HB**, Kim RJ, Parker MA, Fieno DS, Judd RM. Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. *Circulation* 2000; **102**: 1678-1683 [PMID: 11015347 DOI: 10.1161/01.cir.102.14.1678]

21 **Perazzolo Marra M**, Lima JA, Iliceto S. MRI in acute myocardial infarction. *Eur Heart J* 2011; **32**: 284-293 [PMID: 21112897 DOI: 10.1093/eurheartj/ehq409]

22 **Bax JJ**, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. *J Am Coll Cardiol* 1997; **30**: 1451-1460 [PMID: 9362401 DOI: 10.1016/s0735-1097(97)00352-5]

23 **Hamirani YS**, Wong A, Kramer CM, Salerno M. Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. *JACC Cardiovasc Imaging* 2014; **7**: 940-952 [PMID: 25212800 DOI: 10.1016/j.jcmg.2014.06.012]

24 **Eitel I**, de Waha S, Wöhrle J, Fuernau G, Lurz P, Pauschinger M, Desch S, Schuler G, Thiele H. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2014; **64**: 1217-1226 [PMID: 25236513 DOI: 10.1016/j.jacc.2014.06.1194]

25 **Symons R**, Pontone G, Schwitter J, Francone M, Iglesias JF, Barison A, Zalewski J, de Luca L, Degrauwe S, Claus P, Guglielmo M, Nessler J, Carbone I, Ferro G, Durak M, Magistrelli P, Lo Presti A, Aquaro GD, Eeckhout E, Roguelov C, Andreini D, Vogt P, Guaricci AI, Mushtaq S, Lorenzoni V, Muller O, Desmet W, Agati L, Janssens S, Bogaert J, Masci PG. Long-Term Incremental Prognostic Value of Cardiovascular Magnetic Resonance After ST-Segment Elevation Myocardial Infarction: A Study of the Collaborative Registry on CMR in STEMI. *JACC Cardiovasc Imaging* 2018; **11**: 813-825 [PMID: 28823746 DOI: 10.1016/j.jcmg.2017.05.023]

26 **van Kranenburg M**, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, Cottin Y, Atar D, Buser P, Wu E, Lee D, Bodi V, Klug G, Metzler B, Delewi R, Bernhardt P, Rottbauer W, Boersma E, Zijlstra F, van Geuns RJ. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. *JACC Cardiovasc Imaging* 2014; **7**: 930-939 [PMID: 25212799 DOI: 10.1016/j.jcmg.2014.05.010]

27 **Stone GW**, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, Maehara A, Eitel I, Granger CB, Jenkins PL, Nichols M, Ben-Yehuda O. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. *J Am Coll Cardiol* 2016; **67**: 1674-1683 [PMID: 27056772 DOI: 10.1016/j.jacc.2016.01.069]

28 **Bulluck H**, Hammond-Haley M, Fontana M, Knight DS, Sirker A, Herrey AS, Manisty C, Kellman P, Moon JC, Hausenloy DJ. Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping. *J Cardiovasc Magn Reson* 2017; **19**: 57 [PMID: 28764773 DOI: 10.1186/s12968-017-0370-6]

29 **Ingkanisorn WP**, Rhoads KL, Aletras AH, Kellman P, Arai AE. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. *J Am Coll Cardiol* 2004; **43**: 2253-2259 [PMID: 15193689 DOI: 10.1016/j.jacc.2004.02.046]

30 **Kwong RY**, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, Davis RB. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. *Circulation* 2006; **113**: 2733-2743 [PMID: 16754804 DOI: 10.1161/CIRCULATIONAHA.105.570648]

31 **Eitel I**, Kubusch K, Strohm O, Desch S, Mikami Y, de Waha S, Gutberlet M, Schuler G, Friedrich MG, Thiele H. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. *Circ Cardiovasc Imaging* 2011; **4**: 354-362 [PMID: 21518773 DOI: 10.1161/CIRCIMAGING.110.960500]

32 **El Aidi H**, Adams A, Moons KG, Den Ruijter HM, Mali WP, Doevendans PA, Nagel E, Schalla S, Bots ML, Leiner T. Cardiac magnetic resonance imaging findings and the risk of cardiovascular events in patients with recent myocardial infarction or suspected or known coronary artery disease: a systematic review of prognostic studies. *J Am Coll Cardiol* 2014; **63**: 1031-1045 [PMID: 24486280 DOI: 10.1016/j.jacc.2013.11.048]

33 **Mather AN**, Fairbairn TA, Artis NJ, Greenwood JP, Plein S. Timing of cardiovascular MR imaging after acute myocardial infarction: effect on estimates of infarct characteristics and prediction of late ventricular remodeling. *Radiology* 2011; **261**: 116-126 [PMID: 21828188 DOI: 10.1148/radiol.11110228]

34 **Ripa RS**, Nilsson JC, Wang Y, Søndergaard L, Jørgensen E, Kastrup J. Short- and long-term changes in myocardial function, morphology, edema, and infarct mass after ST-segment elevation myocardial infarction evaluated by serial magnetic resonance imaging. *Am Heart J* 2007; **154**: 929-936 [PMID: 17967600 DOI: 10.1016/j.ahj.2007.06.038]

35 **Pontone G**, Guaricci AI, Andreini D, Solbiati A, Guglielmo M, Mushtaq S, Baggiano A, Beltrama V, Fusini L, Rota C, Segurini C, Conte E, Gripari P, Dello Russo A, Moltrasio M, Tundo F, Lombardi F, Muscogiuri G, Lorenzoni V, Tondo C, Agostoni P, Bartorelli AL, Pepi M. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy. *Circ Cardiovasc Imaging* 2016; **9** [PMID: 27729359 DOI: 10.1161/CIRCIMAGING.115.004956]

36 **Scott PA**, Morgan JM, Carroll N, Murday DC, Roberts PR, Peebles CR, Harden SP, Curzen NP. The extent of left ventricular scar quantified by late gadolinium enhancement MRI is associated with spontaneous ventricular arrhythmias in patients with coronary artery disease and implantable cardioverter-defibrillators. *Circ Arrhythm Electrophysiol* 2011; **4**: 324-330 [PMID: 21493964 DOI: 10.1161/CIRCEP.110.959544]

37 **Scott PA**, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis. *Eur J Heart Fail* 2013; **15**: 1019-1027 [PMID: 23558217 DOI: 10.1093/eurjhf/hft053]

38 **Acosta J**, Fernández-Armenta J, Borràs R, Anguera I, Bisbal F, Martí-Almor J, Tolosana JM, Penela D, Andreu D, Soto-Iglesias D, Evertz R, Matiello M, Alonso C, Villuendas R, de Caralt TM, Perea RJ, Ortiz JT, Bosch X, Serra L, Planes X, Greiser A, Ekinci O, Lasalvia L, Mont L, Berruezo A. Scar Characterization to Predict Life-Threatening Arrhythmic Events and Sudden Cardiac Death in Patients With Cardiac Resynchronization Therapy: The GAUDI-CRT Study. *JACC Cardiovasc Imaging* 2018; **11**: 561-572 [PMID: 28780194 DOI: 10.1016/j.jcmg.2017.04.021]

39 **Roes SD**, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan NA, Kaandorp TA, Reiber JH, Zeppenfeld K, Lamb HJ, de Roos A, Schalij MJ, Bax JJ. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. *Circ Cardiovasc Imaging* 2009; **2**: 183-190 [PMID: 19808591 DOI: 10.1161/CIRCIMAGING.108.826529]

40 **Yan AT**, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, Di Carli MF, Reynolds HG, Stevenson WG, Kwong RY. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. *Circulation* 2006; **114**: 32-39 [PMID: 16801462 DOI: 10.1161/CIRCULATIONAHA.106.613414]

41 **Schuster A**, Lange T, Backhaus SJ, Strohmeyer C, Boom PC, Matz J, Kowallick JT, Lotz J, Steinmetz M, Kutty S, Bigalke B, Gutberlet M, de Waha-Thiele S, Desch S, Hasenfuß G, Thiele H, Stiermaier T, Eitel I. Fully Automated Cardiac Assessment for Diagnostic and Prognostic Stratification Following Myocardial Infarction. *J Am Heart Assoc* 2020; **9**: e016612 [PMID: 32873121 DOI: 10.1161/JAHA.120.016612]

42 **Al-Khatib SM**, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation* 2018; **138**: e272-e391 [PMID: 29084731 DOI: 10.1161/CIR.0000000000000549]

43 **Elayi CS**, Charnigo RJ, Heron PM, Lee BK, Olgin JE. Primary Prevention of Sudden Cardiac Death Early Post-Myocardial Infarction: Root Cause Analysis for Implantable Cardioverter-Defibrillator Failure and Currently Available Options. *Circ Arrhythm Electrophysiol* 2017; **10** [PMID: 28630173 DOI: 10.1161/CIRCEP.117.005194]

44 **Ghadri JR**, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, Templin C. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. *Eur Heart J* 2018; **39**: 2032-2046 [PMID: 29850871 DOI: 10.1093/eurheartj/ehy076]

45 **Dote K**, Sato H, Tateishi H, Uchida T, Ishihara M. [Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases]. *J Cardiol* 1991; **21**: 203-214 [PMID: 1841907]

46 **Barrera-Ramirez CF**, Jimenez-Mazuecos JM, Alfonso F. Apical thrombus associated with left ventricular apical ballooning. *Heart* 2003; **89**: 927 [PMID: 12860874 DOI: 10.1136/heart.89.8.927]

47 **Scally C**, Rudd A, Mezincescu A, Wilson H, Srivanasan J, Horgan G, Broadhurst P, Newby DE, Henning A, Dawson DK. Persistent Long-Term Structural, Functional, and Metabolic Changes After Stress-Induced (Takotsubo) Cardiomyopathy. *Circulation* 2018; **137**: 1039-1048 [PMID: 29128863 DOI: 10.1161/CIRCULATIONAHA.117.031841]

48 **Lyon AR**, Akashi YJ. Use of cardiac MRI to diagnose Takotsubo syndrome. *Nat Rev Cardiol* 2015; **12**: 669 [PMID: 26440986 DOI: 10.1038/nrcardio.2015.155]

49 **Eitel I**, Behrendt F, Schindler K, Kivelitz D, Gutberlet M, Schuler G, Thiele H. Differential diagnosis of suspected apical ballooning syndrome using contrast-enhanced magnetic resonance imaging. *Eur Heart J* 2008; **29**: 2651-2659 [PMID: 18820322 DOI: 10.1093/eurheartj/ehn433]

50 **Bratis K**. Cardiac Magnetic Resonance in Takotsubo Syndrome. *Eur Cardiol* 2017; **12**: 58-62 [PMID: 30416553 DOI: 10.15420/ecr.2017:7:2]

51 **Eitel I**, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, Francone M, Desch S, Gutberlet M, Strohm O, Schuler G, Schulz-Menger J, Thiele H, Friedrich MG. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. *JAMA* 2011; **306**: 277-286 [PMID: 21771988 DOI: 10.1001/jama.2011.992]

52 **Gunasekara MY**, Mezincescu AM, Dawson DK. An Update on Cardiac Magnetic Resonance Imaging in Takotsubo Cardiomyopathy. *Curr Cardiovasc Imaging Rep* 2020; **13**: 1-8 [DOI: 10.1007/s12410-020-09536-0]

53 **Avegliano G**, Huguet M, Costabel JP, Ronderos R, Bijnens B, Kuschnir P, Thierer J, Tobón-Gomez C, Martinez GO, Frangi A. Morphologic pattern of late gadolinium enhancement in Takotsubo cardiomyopathy detected by early cardiovascular magnetic resonance. *Clin Cardiol* 2011; **34**: 178-182 [PMID: 21400545 DOI: 10.1002/clc.20877]

54 **Rolf A**, Nef HM, Möllmann H, Troidl C, Voss S, Conradi G, Rixe J, Steiger H, Beiring K, Hamm CW, Dill T. Immunohistological basis of the late gadolinium enhancement phenomenon in tako-tsubo cardiomyopathy. *Eur Heart J* 2009; **30**: 1635-1642 [PMID: 19389788 DOI: 10.1093/eurheartj/ehp140]

55 **Nakamori S**, Matsuoka K, Onishi K, Kurita T, Ichikawa Y, Nakajima H, Ishida M, Kitagawa K, Tanigawa T, Nakamura T, Ito M, Sakuma H. Prevalence and signal characteristics of late gadolinium enhancement on contrast-enhanced magnetic resonance imaging in patients with takotsubo cardiomyopathy. *Circ J* 2012; **76**: 914-921 [PMID: 22293447 DOI: 10.1253/circj.cj-11-1043]

56 **Naruse Y**, Sato A, Kasahara K, Makino K, Sano M, Takeuchi Y, Nagasaka S, Wakabayashi Y, Katoh H, Satoh H, Hayashi H, Aonuma K. The clinical impact of late gadolinium enhancement in Takotsubo cardiomyopathy: serial analysis of cardiovascular magnetic resonance images. *J Cardiovasc Magn Reson* 2011; **13**: 67 [PMID: 22035445 DOI: 10.1186/1532-429X-13-67]

57 **Satoh H**, Sano M, Suwa K, Saitoh T, Nobuhara M, Saotome M, Urushida T, Katoh H, Hayashi H. Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis. *World J Cardiol* 2014; **6**: 585-601 [PMID: 25068019 DOI: 10.4330/wjc.v6.i7.585]

58 **Lyon AR**, Citro R, Schneider B, Morel O, Ghadri JR, Templin C, Omerovic E. Pathophysiology of Takotsubo Syndrome: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2021; **77**: 902-921 [PMID: 33602474 DOI: 10.1016/j.jacc.2020.10.060]

59 **Ojha V**, Khurana R, Ganga KP, Kumar S. Advanced cardiac magnetic resonance imaging in takotsubo cardiomyopathy. *Br J Radiol* 2020; **93**: 20200514 [PMID: 32795180 DOI: 10.1259/bjr.20200514]

60 **Friedrich MG**, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. *J Am Coll Cardiol* 2009; **53**: 1475-1487 [PMID: 19389557 DOI: 10.1016/j.jacc.2009.02.007]

61 **Friedrich MG**, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. *Circulation* 1998; **97**: 1802-1809 [PMID: 9603535 DOI: 10.1161/01.cir.97.18.1802]

62 **Mahrholdt H**, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, Fritz P, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. *Circulation* 2004; **109**: 1250-1258 [PMID: 14993139 DOI: 10.1161/01.CIR.0000118493.13323.81]

63 **Abdel-Aty H**, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, Bock P, Dietz R, Friedrich MG, Schulz-Menger J. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. *J Am Coll Cardiol* 2005; **45**: 1815-1822 [PMID: 15936612 DOI: 10.1016/j.jacc.2004.11.069]

64 **Lurz P**, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, de Waha S, Rommel KP, Lurz JA, Klingel K, Kandolf R, Schuler G, Thiele H, Gutberlet M. Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial. *J Am Coll Cardiol* 2016; **67**: 1800-1811 [PMID: 27081020 DOI: 10.1016/j.jacc.2016.02.013]

65 **Citro R**, Lyon AR, Meimoun P, Omerovic E, Redfors B, Buck T, Lerakis S, Parodi G, Silverio A, Eitel I, Schneider B, Prasad A, Bossone E. Standard and advanced echocardiography in takotsubo (stress) cardiomyopathy: clinical and prognostic implications. *J Am Soc Echocardiogr* 2015; **28**: 57-74 [PMID: 25282664 DOI: 10.1016/j.echo.2014.08.020]

66 **Hunold P**, Schlosser T, Vogt FM, Eggebrecht H, Schmermund A, Bruder O, Schüler WO, Barkhausen J. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. *AJR Am J Roentgenol* 2005; **184**: 1420-1426 [PMID: 15855089 DOI: 10.2214/ajr.184.5.01841420]

67 **Grün S**, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. *J Am Coll Cardiol* 2012; **59**: 1604-1615 [PMID: 22365425 DOI: 10.1016/j.jacc.2012.01.007]

68 **Aquaro GD**, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe A, Todiere G, Lanzillo C, Scatteia A, Di Roma M, Pontone G, Perazzolo Marra M, Barison A, Di Bella G; Cardiac Magnetic Resonance Working Group of the Italian Society of Cardiology. Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With Preserved Systolic Function: ITAMY Study. *J Am Coll Cardiol* 2017; **70**: 1977-1987 [PMID: 29025554 DOI: 10.1016/j.jacc.2017.08.044]

69 **Mahrholdt H**, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. *Circulation* 2006; **114**: 1581-1590 [PMID: 17015795 DOI: 10.1161/CIRCULATIONAHA.105.606509]

70 **Berg J**, Kottwitz J, Baltensperger N, Kissel CK, Lovrinovic M, Mehra T, Scherff F, Schmied C, Templin C, Lüscher TF, Heidecker B, Manka R. Cardiac Magnetic Resonance Imaging in Myocarditis Reveals Persistent Disease Activity Despite Normalization of Cardiac Enzymes and Inflammatory Parameters at 3-Month Follow-Up. *Circ Heart Fail* 2017; **10** [PMID: 29158437 DOI: 10.1161/CIRCHEARTFAILURE.117.004262]

71 **Mavrogeni S**, Petrou E, Kolovou G, Theodorakis G, Iliodromitis E. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance. *Eur Heart J Cardiovasc Imaging* 2013; **14**: 518-525 [PMID: 23324829 DOI: 10.1093/ehjci/jes302]

72 **Georgiopoulos G**, Figliozzi S, Sanguineti F, Aquaro GD, di Bella G, Stamatelopoulos K, Chiribiri A, Garot J, Masci PG, Ismail TF. Prognostic Impact of Late Gadolinium Enhancement by Cardiovascular Magnetic Resonance in Myocarditis: A Systematic Review and Meta-Analysis. *Circ Cardiovasc Imaging* 2021; **14**: e011492 [PMID: 33441003 DOI: 10.1161/CIRCIMAGING.120.011492]

73 **Guo T**, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020; **5**: 811-818 [PMID: 32219356 DOI: 10.1001/jamacardio.2020.1017]

74 **Lala A**, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, Zhao S, Somani S, Van Vleck T, Vaid A, Chaudhry F, De Freitas JK, Fayad ZA, Pinney SP, Levin M, Charney A, Bagiella E, Narula J, Glicksberg BS, Nadkarni G, Mancini DM, Fuster V; Mount Sinai COVID Informatics Center. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. *J Am Coll Cardiol* 2020; **76**: 533-546 [PMID: 32517963 DOI: 10.1016/j.jacc.2020.06.007]

75 **Puntmann VO**, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020; **5**: 1265-1273 [PMID: 32730619 DOI: 10.1001/jamacardio.2020.3557]

76 **Shi S**, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol* 2020; **5**: 802-810 [PMID: 32211816 DOI: 10.1001/jamacardio.2020.0950]

77 **Lindner D**, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, Scherschel K, Kirchhof P, Escher F, Schultheiss HP, Blankenberg S, Püschel K, Westermann D. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. *JAMA Cardiol* 2020; **5**: 1281-1285 [PMID: 32730555 DOI: 10.1001/jamacardio.2020.3551]

78 **Giustino G**, Pinney SP, Lala A, Reddy VY, Johnston-Cox HA, Mechanick JI, Halperin JL, Fuster V. Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: JACC Focus Seminar. *J Am Coll Cardiol* 2020; **76**: 2011-2023 [PMID: 33092737 DOI: 10.1016/j.jacc.2020.08.059]

79 **Li X**, Wang H, Zhao R, Wang T, Zhu Y, Qian Y, Liu B, Yu Y, Han Y. Elevated Extracellular Volume Fraction and Reduced Global Longitudinal Strains in Participants Recovered from COVID-19 without Clinical Cardiac Findings. *Radiology* 2021; **299**: E230-E240 [PMID: 33434112 DOI: 10.1148/radiol.2021203998]

80 **Gravinay P**, Issa N, Girard D, Camou F, Cochet H. CMR and serology to diagnose COVID-19 infection with primary cardiac involvement. *Eur Heart J Cardiovasc Imaging* 2021; **22**: 133 [PMID: 32556106 DOI: 10.1093/ehjci/jeaa169]

81 **Huang L**, Zhao P, Tang D, Zhu T, Han R, Zhan C, Liu W, Zeng H, Tao Q, Xia L. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. *JACC Cardiovasc Imaging* 2020; **13**: 2330-2339 [PMID: 32763118 DOI: 10.1016/j.jcmg.2020.05.004]

82 **Jain SS**, Steele JM, Fonseca B, Huang S, Shah S, Maskatia SA, Buddhe S, Misra N, Ramachandran P, Gaur L, Eshtehardi P, Anwar S, Kaushik N, Han F, Chaudhuri NR, Grosse-Wortmann L. COVID-19 Vaccination-Associated Myocarditis in Adolescents. *Pediatrics* 2021; **148** [PMID: 34389692 DOI: 10.1542/peds.2021-053427]

83 **Tano E**, San Martin S, Girgis S, Martinez-Fernandez Y, Sanchez Vegas C. Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine. *J Pediatric Infect Dis Soc* 2021; **10**: 962-966 [PMID: 34319393 DOI: 10.1093/jpids/piab060]

84 **Bozkurt B**, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. *Circulation* 2021; **144**: 471-484 [PMID: 34281357 DOI: 10.1161/CIRCULATIONAHA.121.056135]

85 **Kim HW**, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, Parker MA, Kim RJ. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol* 2021; **6**: 1196-1201 [PMID: 34185046 DOI: 10.1001/jamacardio.2021.2828]

86 **Larson KF**, Ammirati E, Adler ED, Cooper LT Jr, Hong KN, Saponara G, Couri D, Cereda A, Procopio A, Cavalotti C, Oliva F, Sanna T, Ciconte VA, Onyango G, Holmes DR, Borgeson DD. Myocarditis After BNT162b2 and mRNA-1273 Vaccination. *Circulation* 2021; **144**: 506-508 [PMID: 34133884 DOI: 10.1161/CIRCULATIONAHA.121.055913]

87 **Montgomery J**, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT Jr. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol* 2021; **6**: 1202-1206 [PMID: 34185045 DOI: 10.1001/jamacardio.2021.2833]

88 **Marshall M**, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, Shaughnessy R, Caron R, Fuss C, Corbin KJE, Emuren L, Faherty E, Hall EK, Di Pentima C, Oster ME, Paintsil E, Siddiqui S, Timchak DM, Guzman-Cottrill JA. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. *Pediatrics* 2021; **148** [PMID: 34088762 DOI: 10.1542/peds.2021-052478]

89 **Vollmann D**, Eiffert H, Schuster A. Acute Perimyocarditis Following First Dose of mRNA Vaccine Against COVID-19. *Dtsch Arztebl Int* 2021; **118**: 546 [PMID: 34515024 DOI: 10.3238/arztebl.m2021.0288]

90 **Shi S**, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, Huang H, Yang B, Huang C. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. *Eur Heart J* 2020; **41**: 2070-2079 [PMID: 32391877 DOI: 10.1093/eurheartj/ehaa408]

91 **Metkus TS**, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, Michos ED, Nolley EP, Post WS, Resar JR, Thiemann DR, Trost JC, Hasan RK. Myocardial Injury in Severe COVID-19 Compared With Non-COVID-19 Acute Respiratory Distress Syndrome. *Circulation* 2021; **143**: 553-565 [PMID: 33186055 DOI: 10.1161/CIRCULATIONAHA.120.050543]

92 **Sanghvi SK**, Schwarzman LS, Nazir NT. Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis. *Diagnostics (Basel)* 2021; **11** [PMID: 33467705 DOI: 10.3390/diagnostics11010130]

93 **Mitrani RD**, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. *Heart Rhythm* 2020; **17**: 1984-1990 [PMID: 32599178 DOI: 10.1016/j.hrthm.2020.06.026]

94 **Corrado D**, Pelliccia A, Heidbuchel H, Sharma S, Link M, Basso C, Biffi A, Buja G, Delise P, Gussac I, Anastasakis A, Borjesson M, Bjørnstad HH, Carrè F, Deligiannis A, Dugmore D, Fagard R, Hoogsteen J, Mellwig KP, Panhuyzen-Goedkoop N, Solberg E, Vanhees L, Drezner J, Estes NA 3rd, Iliceto S, Maron BJ, Peidro R, Schwartz PJ, Stein R, Thiene G, Zeppilli P, McKenna WJ; Section of Sports Cardiology, European Association of Cardiovascular Prevention and Rehabilitation. Recommendations for interpretation of 12-lead electrocardiogram in the athlete. *Eur Heart J* 2010; **31**: 243-259 [PMID: 19933514 DOI: 10.1093/eurheartj/ehp473]

95 **Marshall L**, Lee KK, Stewart SD, Wild A, Fujisawa T, Ferry AV, Stables CL, Lithgow H, Chapman AR, Anand A, Shah ASV, Dhaun N, Strachan FE, Mills NL, Ross MD. Effect of Exercise Intensity and Duration on Cardiac Troponin Release. *Circulation* 2020; **141**: 83-85 [PMID: 31887079 DOI: 10.1161/CIRCULATIONAHA.119.041874]

96 **Shave R**, Oxborough D. Exercise-induced cardiac injury: evidence from novel imaging techniques and highly sensitive cardiac troponin assays. *Prog Cardiovasc Dis* 2012; **54**: 407-415 [PMID: 22386291 DOI: 10.1016/j.pcad.2012.01.007]

97 **Middleton N**, Shave R, George K, Whyte G, Hart E, Atkinson G. Left ventricular function immediately following prolonged exercise: A meta-analysis. *Med Sci Sports Exerc* 2006; **38**: 681-687 [PMID: 16679983 DOI: 10.1249/01.mss.0000210203.10200.12]

98 **Carrió I**, Serra-Grima R, Berná L, Estorch M, Martinez-Duncker C, Ordoñez J. Transient alterations in cardiac performance after a six-hour race. *Am J Cardiol* 1990; **65**: 1471-1474 [PMID: 2353653 DOI: 10.1016/0002-9149(90)91357-c]

99 **La Gerche A**, Connelly KA, Mooney DJ, MacIsaac AI, Prior DL. Biochemical and functional abnormalities of left and right ventricular function after ultra-endurance exercise. *Heart* 2008; **94**: 860-866 [PMID: 17483127 DOI: 10.1136/hrt.2006.101063]

100 **Caselli S**, Maron MS, Urbano-Moral JA, Pandian NG, Maron BJ, Pelliccia A. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2014; **114**: 1383-1389 [PMID: 25217454 DOI: 10.1016/j.amjcard.2014.07.070]

101 **Morganroth J**, Maron BJ, Henry WL, Epstein SE. Comparative left ventricular dimensions in trained athletes. *Ann Intern Med* 1975; **82**: 521-524 [PMID: 1119766 DOI: 10.7326/0003-4819-82-4-521]

102 **D'Ascenzi F**, Anselmi F, Piu P, Fiorentini C, Carbone SF, Volterrani L, Focardi M, Bonifazi M, Mondillo S. Cardiac Magnetic Resonance Normal Reference Values of Biventricular Size and Function in Male Athlete's Heart. *JACC Cardiovasc Imaging* 2019; **12**: 1755-1765 [PMID: 30553678 DOI: 10.1016/j.jcmg.2018.09.021]

103 **Pluim BM**, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete's heart. A meta-analysis of cardiac structure and function. *Circulation* 2000; **101**: 336-344 [PMID: 10645932 DOI: 10.1161/01.cir.101.3.336]

104 **Galanti G**, Stefani L, Mascherini G, Di Tante V, Toncelli L. Left ventricular remodeling and the athlete's heart, irrespective of quality load training. *Cardiovasc Ultrasound* 2016; **14**: 46 [PMID: 27855701 DOI: 10.1186/s12947-016-0088-x]

105 **Swoboda PP**, McDiarmid AK, Erhayiem B, Broadbent DA, Dobson LE, Garg P, Ferguson C, Page SP, Greenwood JP, Plein S. Assessing Myocardial Extracellular Volume by T1 Mapping to Distinguish Hypertrophic Cardiomyopathy From Athlete's Heart. *J Am Coll Cardiol* 2016; **67**: 2189-2190 [PMID: 27151352 DOI: 10.1016/j.jacc.2016.02.054]

106 **Domenech-Ximenos B**, Sanz-de la Garza M, Prat-González S, Sepúlveda-Martínez A, Crispi F, Duran-Fernandez K, Perea RJ, Bijnens B, Sitges M. Prevalence and pattern of cardiovascular magnetic resonance late gadolinium enhancement in highly trained endurance athletes. *J Cardiovasc Magn Reson* 2020; **22**: 62 [PMID: 32878630 DOI: 10.1186/s12968-020-00660-w]

107 **Rubinshtein R**, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. *Circ Heart Fail* 2010; **3**: 51-58 [PMID: 19850699 DOI: 10.1161/CIRCHEARTFAILURE.109.854026]

108 **Prakken NH**, Velthuis BK, Teske AJ, Mosterd A, Mali WP, Cramer MJ. Cardiac MRI reference values for athletes and nonathletes corrected for body surface area, training hours/week and sex. *Eur J Cardiovasc Prev Rehabil* 2010; **17**: 198-203 [PMID: 20042862 DOI: 10.1097/HJR.0b013e3283347fdb]

109 **Pelliccia A**, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. *Ann Intern Med* 1999; **130**: 23-31 [PMID: 9890846 DOI: 10.7326/0003-4819-130-1-199901050-00005]

110 **Gati S**, Sharma S. Determinants of the athlete's heart: a cardiovascular magnetic resonance imaging study. *Eur J Prev Cardiol* 2020; **27**: 536-539 [PMID: 31403882 DOI: 10.1177/2047487319870339]

111 **Gati S**, Sharma S, Pennell D. The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Highly Trained Athletes. *JACC Cardiovasc Imaging* 2018; **11**: 247-259 [PMID: 29413645 DOI: 10.1016/j.jcmg.2017.11.016]

112 **Heidbüchel H**, Hoogsteen J, Fagard R, Vanhees L, Ector H, Willems R, Van Lierde J. High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. *Eur Heart J* 2003; **24**: 1473-1480 [PMID: 12919770 DOI: 10.1016/s0195-668x(03)00282-3]

113 **Zaidi A**, Sheikh N, Jongman JK, Gati S, Panoulas VF, Carr-White G, Papadakis M, Sharma R, Behr ER, Sharma S. Clinical Differentiation Between Physiological Remodeling and Arrhythmogenic Right Ventricular Cardiomyopathy in Athletes With Marked Electrocardiographic Repolarization Anomalies. *J Am Coll Cardiol* 2015; **65**: 2702-2711 [PMID: 26112193 DOI: 10.1016/j.jacc.2015.04.035]

114 **La Gerche A**, Claessen G, Van de Bruaene A, Pattyn N, Van Cleemput J, Gewillig M, Bogaert J, Dymarkowski S, Claus P, Heidbuchel H. Cardiac MRI: a new gold standard for ventricular volume quantification during high-intensity exercise. *Circ Cardiovasc Imaging* 2013; **6**: 329-338 [PMID: 23258478 DOI: 10.1161/CIRCIMAGING.112.980037]

115 **Le TT**, Bryant JA, Ting AE, Ho PY, Su B, Teo RC, Gan JS, Chung YC, O'Regan DP, Cook SA, Chin CW. Assessing exercise cardiac reserve using real-time cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2017; **19**: 7 [PMID: 28110638 DOI: 10.1186/s12968-017-0322-1]

116 **La Gerche A**, Claessen G, Dymarkowski S, Voigt JU, De Buck F, Vanhees L, Droogne W, Van Cleemput J, Claus P, Heidbuchel H. Exercise-induced right ventricular dysfunction is associated with ventricular arrhythmias in endurance athletes. *Eur Heart J* 2015; **36**: 1998-2010 [PMID: 26038590 DOI: 10.1093/eurheartj/ehv202]

117 **Maestrini V**, Merghani A, Rosmini S, Cox A, Bulluck H, Culotta V, Cheang M, Fontana M, Treibel TA, Abdel-Gadir A, Sharma S, Moon J. CMR findings in high endurance veteran athletes - a 247 subject study. *J Cardiovasc Magn Reson* 2016; **18**: O38 [DOI: 10.1186/1532-429X-18-S1-O38]

118 **La Gerche A**, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, Macisaac AI, Heidbüchel H, Prior DL. Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. *Eur Heart J* 2012; **33**: 998-1006 [PMID: 22160404 DOI: 10.1093/eurheartj/ehr397]

119 **Breuckmann F**, Möhlenkamp S, Nassenstein K, Lehmann N, Ladd S, Schmermund A, Sievers B, Schlosser T, Jöckel KH, Heusch G, Erbel R, Barkhausen J. Myocardial late gadolinium enhancement: prevalence, pattern, and prognostic relevance in marathon runners. *Radiology* 2009; **251**: 50-57 [PMID: 19332846 DOI: 10.1148/radiol.2511081118]

120 **Zorzi A**, Perazzolo Marra M, Rigato I, De Lazzari M, Susana A, Niero A, Pilichou K, Migliore F, Rizzo S, Giorgi B, De Conti G, Sarto P, Serratosa L, Patrizi G, De Maria E, Pelliccia A, Basso C, Schiavon M, Bauce B, Iliceto S, Thiene G, Corrado D. Nonischemic Left Ventricular Scar as a Substrate of Life-Threatening Ventricular Arrhythmias and Sudden Cardiac Death in Competitive Athletes. *Circ Arrhythm Electrophysiol* 2016; **9** [PMID: 27390211 DOI: 10.1161/CIRCEP.116.004229]

121 **Androulakis E**, Swoboda PP. The Role of Cardiovascular Magnetic Resonance in Sports Cardiology; Current Utility and Future Perspectives. *Curr Treat Options Cardiovasc Med* 2018; **20**: 86 [PMID: 30167977 DOI: 10.1007/s11936-018-0679-y]

122 **Pujadas S**, Doñate M, Li CH, Merchan S, Cabanillas A, Alomar X, Pons-Llado G, Serra-Grima R, Carreras F. Myocardial remodelling and tissue characterisation by cardiovascular magnetic resonance (CMR) in endurance athletes. *BMJ Open Sport Exerc Med* 2018; **4**: e000422 [PMID: 30498573 DOI: 10.1136/bmjsem-2018-000422]

123 **Plácido R**, Cunha Lopes B, Almeida AG, Rochitte CE. The role of cardiovascular magnetic resonance in takotsubo syndrome. *J Cardiovasc Magn Reson* 2016; **18**: 68 [PMID: 27729054 DOI: 10.1186/s12968-016-0279-5]

**Footnotes**

**Conflict-of-interest statement:** Allauthors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model**: Single blind

**Peer-review started:** March 18, 2021

**First decision:** September 29, 2021

**Article in press:** April 3, 2022

**Specialty type:** Cardiac and cardiovascular systems

**Country/Territory of origin:** Australia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kwok W, United States; Roncalli J, France **S-Editor:** Ma YJ **L-Editor:** Kerr C **P-Editor:** Ma YJ


**Figure Legends**

****


**Figure 1 Cardiac magnetic resonance imaging of acute myocardial infarction.** A: short axis mid-ventricular image demonstrating almost full-thickness transmural late gadolinium enhancement (LGE) in posterolateral wall (yellow arrow); B: four-chamber image demonstrating focal LGE in lateral wall (red arrow); C: short axis image demonstrating > 75% transmural LGE in lateral wall (orange arrow).



**Figure 2 Cardiac magnetic resonance imaging of Takotsubo cardiomyopathy.** Typical apical ballooning seen in takotsubo syndrome. A, B: Cine four-chamber in late diastole and systole respectively; C, D: Two-chamber view in late diastole and systole respectively. Modified from Plácido *et al*[123] and licensed under the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>).

****

**Figure 3 Cardiac magnetic resonance imaging of acute myocarditis**. A: four-chamber image demonstrating LGE in septal wall in a mid-wall pattern (yellow arrow); B: short axis mid-left ventricular image demonstrating LGE in anteroseptal wall in a mid-wall pattern (red arrow); C: two-chamber image demonstrating LGE in the anterior wall in a mid-wall pattern (orange yellow).



**Figure 4 COVID-19 related cardiac dysfunction on cardiac magnetic resonance imaging.** cardiac magnetic resonance imaging of an adult woman with COVID-19-related perimyocarditis. A, B: significantly raised native T1 and native T2 in myocardial mapping acquisitions; C, D: pericardial effusion and enhancement (yellow arrowheads) and epicardial and intramyocardial enhancement (white arrowheads) using LGE acquisition. Modified from Puntmann *et al*[75] and licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).



**Figure 5** **Cardiac magnetic resonance imaging of athlete’s heart syndrome.** A: cardiac magnetic resonance imaging of an endurance athlete. Increased right and left ventricular volumes. Overall muscle mass may be increased although wall thickness remains within standard reference range[102]; B: A 51-year-old athlete training 7 h/wk in the last 30 years. The short-axis view shows subepicardial late gadolinium enhancement (LGE) in the inferior apical wall; C: A 55-year-old athlete training 8 h/wk in the last 30 years. Mild intramyocardial LGE is the lateral wall is shown in the four-chamber view; D: A 55-year-old athlete training 10 h/wk in the last 28 years. Mesocardial LGE in the apical-septal wall shown in three-chamber view image. Reproduced from Pujadas *et al*[122] and licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

**Table 1 Cardiac magnetic resonance imaging features**

|  |  |
| --- | --- |
| **Condition** | **Cardiac magnetic resonance imaging features** |
| Myocardial infarction | **< 1 mo** |
| * Myocardial oedema present on T2-weighted images, T2 mapping and T1 mapping |
| * Microvascular obstruction revealed as a hypointense core within hyperintense infarct zone in area of LGE |
| * Infarct size can be calculated using pre and post-contrast T1-weighted mapping and ECV assessment |
| * Myocardial necrosis/scar by LGE in a subendocardial or full-thickness pattern within a coronary artery territory |
| **Additionally at < 6 mo** |
| * T2-weighted hyperintensity on double inversion recovery turbo spin echo |
| Takotsubo syndrome | * Can help distinguish coexisting CAD or acute myocarditis * LGE typically absent |
| * Myocardial oedema present on T2-weighted images, T2 mapping and T1 mapping |
| * Accurate assessment of WMAs on cine imaging |
| * Can be useful to identify ventricular thrombus |
| Myocarditis | * Inflammatory hyperaemia demonstrated on T1-weighted images |
| * Myocardial oedema on T2-weighted images |
| * Myocardial necrosis/scar by LGE in a subepicardial or mid-wall pattern |
| * Greater T1 and T2 increases with acute inflammation |
| * Pericardial effusion |
| COVID-19 related cardiac dysfunction | * Features similar to that of acute myocarditis |
| * Myocardial oedema on T2-weighted images |
| * Myocardial necrosis/scar by LGE in a subepicardial or mid-wall pattern |
| * Myocardial fibrosis using T1-weighted mapping and ECV assessment |
| * Can be useful to identify ventricular thrombus and pericardial effusion |
| Athlete’s heart | * LVH typically < 12 mm |
| * Lower ECV with LVH compared to HCM |
| * RV dilatation seen on cine imaging |
| * LGE focal and generally at the RV insertion points |

LGE: late gadolinium enhancement; ECV: extra-cellular volume; CAD: Coronary artery disease; WMAs: Wall motion abnormalities; LVH: left ventricular hypertrophy; HCM: hypertrophic cardiomyopathy; RV: right ventricular.

**Table 2 Lake Louise consensus criteria for myocarditis on cardiac magnetic resonance imaging**

|  |
| --- |
| Two out of three criteria must be met to be consistent with myocardial inflammation: |
| Regional or global myocardial signal intensity increase in T2-weighted images |
| Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images |
| At least one focal lesion with nonischaemic regional distribution in inversion recovery-prepared gadolinium enhanced T1-weighted images (late gadolinium enhancement) |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**